Viagra (sildenafil citrate) began life as a Pfizer trial for high blood pressure and chest pain. It showed no promise and was one financial quarter away from the garbage bin when a trial debrief of some Welsh miners revealed an odd side effect: more boners. After scratching together enough money for an impotence study, the drug began its legendary ascent (ahem). Approved by the FDA in 1998 it was an instant sensation, to a degree that Pfizer never remotely considered. It would go on to make $32.6B during its 20-year exclusive license. Bloomberg talks to some corporate and industry insiders about the transforming power of a little blue pill.